Board of DirectorsExperienced and committed leadership
Garth Selvey has a BSc in Physics and Electronic Engineering from the University of Manchester and has spent over 36 years in the computer industry in technical, product, sales and marketing roles.
Brings to the Board – Extensive experience of the listed sector and leading companies.
Andrew Newland is Chief Executive of ANGLE plc. He has an MA in Engineering Science from the University of Cambridge and is a qualified Chartered Accountant. He has over 20 years of medical diagnostics experience and has specialised in the liquid biopsy space for the last 12 years.
Andrew founded ANGLE in 1994. In 1999, Andrew led the team that founded the medical diagnostic company Acolyte Biomedica. Acolyte was the first ever spin-out of the Defence Science and Technology Laboratory (Dstl) Porton Down, which specialised in rapid diagnosis of MRSA, the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.
Brings to the Board – Over 30 years’ experience of setting up, leading and building technology-based businesses, over 20 years leading specialist medtech businesses, and 12 years in the liquid biopsy space.
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over 30 years and is an expert on the development and growth of new technology-based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy with a special work focus, then in management consulting within KPMG's High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
Brings to the Board – Over 30 years’ experience in finance and technology-based businesses, and 12 years in the liquid biopsy space.
Brian Howlett has a wealth of international experience as a medtech leader which he is currently applying in a Non-executive/Chairman capacity for neuro-endovascular company Oxford Endovascular Ltd, and medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms, from 2005 to 2009. During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in the EU, USA, Russia and Brazil.
Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the corporation’s European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in UK, Scandinavia and the Benelux markets within Fisons plc.
Brings to the Board – Extensive commercial operations experience of the medtech sector.
Dr. Jan Groen is currently the CEO and Chairman at Intravacc B.V. a contract development and manufacturing organisation for infectious disease and therapeutic vaccines in the Netherlands. Jan was previously the CEO of MDxHealth, a Euronext listed genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers. MDxHealth’s genomic tests are setting new standards in prostate and bladder cancer diagnosis, where they have helped over 100,000 patients avoid unnecessary diagnostic procedures.
Brings to the Board – Expertise in new product development, including development and successful commercialisation of CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA.